Stratec stock
SBS.DEXETRAStratec SE, HealthcareISIN DE000STRA555WKN STRA55
52Score 52 out of 100, Neutral
Price and trend
83 / 100
Price history
+23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 32% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 73).
The price is at its 52-week high. Largest decline in 20 years: 89% (September 2021 to June 2026).
Chart figures for advanced users
- SMA 50$26.19
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.45
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)73
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.31
- The lowest closing price of the last twelve months.
- Resistance$29.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Stratec SE belongs to the Medical (Devices) industry (Germany) and, with a market value of $360.32M, is number 86 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $277.98M (down 2.6% year on year) and a loss of $268.16K.
- For fiscal 2026, analysts expect on average revenue of $279.53M (up 0.6%) and adjusted earnings per share of $1.69 (up 15.3%).
Show more
- MEQIRI Score 52 out of 100 (Neutral): rank 360 of 702 in Healthcare, median 53.
- Our model puts fair value at $30.94, with the price 4% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 19.7% a year through 2028 (estimates from 5 analysts).
Weaknesses
- Margin fallingOperating margin 3.4%, average of the prior years 13% (to 2024).Profitability 17
- Loss-makingLoss of $437.7K over the last 12 months.Fundamentals 50
- Turned to a lossEarnings per share from $2.68 in 2020 to −$0.02.Growth 38
Its standout strengths are momentum and technical analysis, while capital allocation and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $23.80 and expensive above $44.20 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 7.5%. At 8.5% the fair value would be $25.49, at 6.5% it would be $38.96.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 4.8% on the twelve months before. Revenue turned from negative at the start of the period to positive ($277.98M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 26%, operating 3%, net 0%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 31 Mar 2027in 138 days
- Last reported
- 14 Aug 2026EPS reported $0.42 (expected $0.21)above expectations
Analyst estimates
- Earnings per share
- $1.69+5.0%
- Revenue
- $279.53M−5.5%
- Earnings per share
- $1.98+0.8%
- Revenue
- $297.51M−5.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +11.2%2026 guidance confirmed, adjusted EBIT margin about at last year's level of 10%; the year is again heavily weighted toward the fourth quarter.
“Adjusted EBIT margin is expected to be approximately on the previous year's level, which was 10% adjusted EBIT.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 14 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Stratec
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- CellaVisionCEVI.ST $483.11M80
- Metall ZugMETN.SW $460.29M40
- Revenio GroupREG1V.HE $419.17M47
- NeuroPaceNPCE $412.58M32
- ImplanticaIMP-A-SDB.ST $400.4M50
- CerusCERS $391.79M33
- Treace Medical ConceptsTMCI $350.09M48
- CapsoVisionCV $333.63M38
ETFs that hold Stratec
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.00% | 0.39% | €1.49B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.